eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2020
vol. 12
 
Share:
Send email
Share:
abstract:
Original paper

One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients

Vitaliana De Sanctis
1
,
Daniela Musio
2
,
Francesca De Felice
3
,
Francesco Marampon
3
,
Maurizio Valeriani
1
,
Paolo Bonome
1
,
Dimitri Anzellini
1
,
Giuseppe Facondo
1
,
Gianluca Vullo
1
,
Maria Massaro
1
,
Mario Di Staso
4
,
Pierluigi Bonfili
5
,
Agnieszka Chalaszczyk
6
,
Giovanni Luca Gravina
6
,
Vincenzo Tombolini
3
,
Mattia Falchetto Osti
1

  1. Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, “Sapienza” University of Rome, S Andrea Hospital, Rome, Italy
  2. Radiotherapy Oncology, Policlinico Umberto I, Rome, Italy
  3. Department of Radiotherapy, “Sapienza” University of Rome, Policlinico Umberto I, Rome, Italy
  4. Radiotherapy Oncology, S Salvatore Hospital, L’Aquila, Italy
  5. Radiotherapy Oncology, Spirito Santo Hospital, Pescara, Italy
  6. Radiotherapy Oncology, University of L’Aquila, Italy
J Contemp Brachytherapy 2020; 12, 2: 124–130
DOI: https://doi.org/10.5114/jcb.2020.94581
Online publish date: 2020/04/30
View full text Get citation
 
Purpose
The aim of the study was to report survival outcomes and toxicities incidence by using one-week vaginal brachytherapy (VBT) schedule in intermediate- and high-intermediate-risk endometrial cancer patients.

Material and methods
One hundred and eight patients were treated with exclusive high-dose-rate (HDR) brachytherapy short schedule (7 Gy/fraction/every other day/1 week). Acute and late rectal, urinary, and vaginal toxicities were recorded according to radiation therapy oncology group (RTOG) scores and late effects normal tissue task force – subjective, objective, management, analytic (LENT-SOMA) scores, respectively. Overall survival (OS), cause specific survival (CSS), and disease-free survival (DFS) were evaluated.

Results
Median follow-up was 44 months (range, 6-117 months). The 5-year OS, CSS, and DFS rates were 92.7%, 96.4%, and 89.5%, respectively. Seven of 108 (6.5%) patients relapsed after a median time of 31 months (range, 5-56 months). Death occurred in 6 patients. Four patients died for intercurrent causes without an evidence of disease. Acute bladder toxicity G1-G2 was reported in 11 of 108 (10%) patients, vaginal toxicity G1-G2 in 6 of 108 (5.5%), and gastrointestinal toxicity was observed in 3 of 108 (3%) patients. Late bladder and gastrointestinal G1 toxicities were reported in 4 of 108 (4%) and 1 of 108 (1%) patients, respectively. Late vaginal toxicity (G1-G2) was recorded in 3 of 108 (3%) cases. No grade 3-4 bladder, vaginal, and gastrointestinal toxicities were noted.

Conclusions
Exclusive short course adjuvant VBT is an effective treatment in patients with early-stage endometrial cancer and provides good outcomes in terms of disease local control and DFS, with low rates of toxicity profile.

keywords:

endometrial cancer, brachytherapy, vaginal vault, toxicity, survival, local recurrence

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.